|
|
|
|
Chronic Lymphocytic Leukemia News Headlines
|
|
|
|
|
|
|
All Recent Chronic Lymphocytic Leukemia News Headlines |
|
|
|
|
How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia
Samples submitted for a suspect of chronic lymphocytic leukemia are the most frequently observed in flow cytometry laboratories. These cases require not only a precise and prompt diagnosis but also an evaluation on the possibility of performing additional prognostic tests. We will propose two sequential flow cytometry panels and a personal opinion on how to manage these samples for both diagnostic and prognostic assessment, taking into account the published guidelines and recommendations. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)...
POSTED 06/30/2009 at 06:00 PM --
|
Common genetic variants in candidate genes and risk of familial lymphoid malignancies
Familial aggregation, linkage and case[ndash]control studies support the role of germline genes in the aetiology of lymphoid malignancies. To further examine the role of genetic variation underlying susceptibility, we analysed 1536 single nucleotide polymorphisms in 152 genes involved in apoptosis, DNA repair, immune response and oxidative stress pathways among a unique sample of 165 unrelated familial cases including patients with chronic lymphocytic leukaemia (CLL), Waldenström macroglobulinaemia (WM) and Hodgkin lymphoma (HL), and 107 spouse controls. We confirmed previous studies showing a polymorphism in the IL10 promoter (rs1800890/-3575T>A) to be associated with non-Hodgkin lymphoma, as this allele was found to be associated with both CLL and WM. We also confirmed the role of IL6 v......
POSTED 06/30/2009 at 06:00 PM --
|
Clinical pathological and epidemiological assessment of morphologically and immunologically confirmed canine leukaemia
This study strengthens the hypothesis that acute leukaemias give rise to more profound cytopenias, affecting more cell lines, than chronic leukaemias. (Source: Veterinary and Comparative Oncology)...
POSTED 06/30/2009 at 06:00 PM --
|
Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia
The objective of this study was to confirm previous results regarding the differential expression and prognostic significance of the circadian gene CRY1 in chronic lymphocytic leukemia (CLL) patients and its relationship with the expression of other circadian genes and well-established prognostic markers. We also aimed to investigate whether the peripheral circadian machinery may be deregulated in CLL cells. The expression of CRY1, PER1, and PER2 was determined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in 116 CLL patients. The expression at sequential time points over a 24-h period was measured in six CLL patients and six normal donors. We confirmed the differential expression of CRY1 in ZAP-70+/CD38+ and ZAP-70[minus]/CD38[minus] CLL samples. Subgroups formed a......
POSTED 06/29/2009 at 06:00 PM --
|
Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.
Authors: Robak T
Chronic lymphoid leukemias include well defined mature B-cell and T-cell neoplasms with diverse natural history and specific morphological, immunophenotypic and molecular characteristics. The most common adult leukemia in the Western world is chronic lymphocytic leukemia (CLL). Rarer indolent lymphoid leukemias include prolymphocytic leukemia, hairy cell leukemia, large granular lymphocyte leukemia and T-cell leukemia/lymphoma. Recently, several new agents have been explored and have shown promise in CLL treatment. Novel therapies are being evaluated both in pre-clinical studies and in early clinical trials. These treatments include new purine nucleoside analogs, antisense oligonucleotides, agents targeting the antiapoptotic Bcl-2 family of proteins, receptors involved......
POSTED 06/27/2009 at 10:08 PM --
|
CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia
Abstract: Chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) share many features and their differential diagnosis may be challenging, especially when a leukemic picture alone is present. Monoclonal antibody panels are often useful, with CD23 being the most reliable. However, MCL diagnosis should be confirmed by immunohistochemical cyclin D1 detection, sometimes with equivocal or even negative results. Other cytofluorimetric, cytogenetics or molecular techniques are reliable but not widely available.B-CLL leukemic cells express CD200, a membrane glycoprotein belonging to the immunoglobulin superfamily. We investigated its expression on fresh neoplastic cells of 93 patients with a CD5+ lymphoproliferative disease (79 selected B-CLL and 14 MCL in leukemic phase). Although the......
POSTED 06/26/2009 at 09:24 AM --
|
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
Abstract: An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was transfected into the NK-92 cell line by electroporation. In contrast to cDNA, mRNA resulted in high transfection efficiency (47.2±8% versus (Source: Leukemia Research)...
POSTED 06/26/2009 at 09:24 AM --
|
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene
Abstract: We used BAC array-based CGH to detect genomic imbalances in 187 CLL cases. Submicroscopic deletions of chromosome 22q11 were observed in 28 cases (15%), and the frequency of these deletions was second only to loss of the 13q14 region, the most common genomic aberration in CLL. Oligonucleotide-based array CGH analysis showed that the 22q11 deletions ranged in size from 0.34Mb up to ∼1Mb. The minimally deleted region included the ZNF280A, ZNF280B, GGTLC2, and PRAME genes. Quantitative real-time PCR revealed that ZNF280A, ZNF280B, and PRAME mRNA expression was significantly lower in the 22q11 deletion cases compared to non-deleted cases. (Source: Leukemia Research)...
POSTED 06/26/2009 at 09:24 AM --
|
GRAND ROUNDS: Evolving Health Effects of Pneumocystis: One Hundred Years of Progress in Diagnosis and Treatment
We present a patient with chronic lymphocytic leukemia who died from Pneumocystis pneumonia (PCP) despite appropriate anti-Pneumocystis therapy. Although substantial advances in diagnosis, treatment, and prevention of PCP have decreased its frequency and improved prognosis, PCP continues to be seen in both HIV-infected patients and patients receiving immunosuppressive medications. Pneumocystis species comprise a family of fungi, each of which appears to be able to infect only 1 host species. Pneumocystis has a worldwide distribution. Immunocompetent hosts clear infection without obvious clinical consequences. Pneumocystis has been identified in patients with other diseases such as chronic obstructive pulmonary disease, although its clinical impact is uncertain. Immunocompromised patients d......
POSTED 06/22/2009 at 06:00 PM --
|
Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing
We describe here an improved test and report its use with samples from the Leukaemia Research Fund CLL4 randomised clinical trial and previously treated patients. ITRT was performed by the tumour response to anti-neoplastic compounds (TRAC) assay, a modification of the differential staining cytotoxicity (DiSC) assay. Improvements included drying drugs into wells before assay and using the Octospot system to cytocentrifuge eight spots of cells onto one microscope slide. We successfully tested 765/782 (98%) cellular blood samples received within 48 h of phlebotomy. Cross-resistance (Pearson's r > 0·7) in untreated CLL was found between similar drugs. Mitoxantrone (r = 0·31), cyclophosphamide (r = 0·35) and pentostatin (r = 0·29) had low cross-resistance with fludarabine. Treatment result......
POSTED 06/21/2009 at 06:00 PM --
|
Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH
Cancer Biotherapy & Radiopharmaceuticals Jun 2009, Vol. 24, No. 3: 353-355. (Source: Cancer Biotherapy and Radiopharmaceuticals)...
POSTED 06/19/2009 at 09:36 AM --
|
miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?
miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?
Leukemia advance online publication, June 18, 2009. doi:10.1038/leu.2009.125
Authors: B Cardinaud, C Moreilhon, B Marcet, K Robbe-Sermesant, K LeBrigand, B Mari, V Eclache, F Cymbalista, S Raynaud
& P Barbry (Source: Leukemia)...
POSTED 06/17/2009 at 06:00 PM --
|
Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL)
(Source: Blood)...
POSTED 06/17/2009 at 06:00 PM --
|
p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia
(Source: Blood)...
POSTED 06/17/2009 at 06:00 PM --
|
Chronic lymphocytic leukemia
Patients with purine analogue-refractory chronic lymphocytic leukemia (CLL) have short survival and limited treatment options. Defining the best salvage strategies for this population is challenging, because limited data are available from clinical trials, and because studies have enrolled mixed populations (patients with recurrent and refractory disease or patients with refractory disease and Richter transformation). Moreover, patients with refractory CLL have a high incidence of unfavorable molecular and clinical features, such as high-risk genomic profiles, unmutated immunoglobulin heavy-chain genes, expression of zeta-chain-associated protein kinase 70, and bulky lymphadenopathies. These patients are also severely immunosuppressed because of the underlying disease and the treatments re......
POSTED 06/16/2009 at 06:00 PM --
|
Bendamustine therapy in chronic lymphocytic leukemia
Expert Opinion on Pharmacotherapy , July 2009, Vol. 10, No. 10, Pages 1687-1698. (Source: Expert Opinion: Expert Opinion on Pharmacotherapy: Table of Contents)...
POSTED 06/16/2009 at 12:06 AM --
|
A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene
The ATM-p53 pathway plays an important role in the biology of chronic lymphocytic leukemia (CLL). Its functional integrity can be probed by exposing CLL cells to ionizing radiation (IR) and measuring levels of p53 protein and one of its transcriptional targets, the cyclin-dependent kinase inhibitor p21. We have previously identified two abnormal p53/p21 response patterns associated with inactivating mutations of TP53 and ATM, respectively. Here, we describe a third abnormal response pattern characterized by failure of p21 protein accumulation despite a normal p53 protein response. This so-called "type C" response was detected in 10.6% of unselected patients and was associated with resistance of CLL cells to p53-dependent killing by IR, with the clinically more aggressive variant of CLL cha......
POSTED 06/14/2009 at 11:00 PM --
|
Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is currently being investigated as a therapeutic agent for a variety of malignancies, as it triggers apoptosis specifically in transformed cells. However, TRAIL use as a stand alone therapeutic is hampered by the fact that many primary tumor cells are resistant to TRAIL-mediated apoptosis. Here, we investigated the extent to which pretreatment of TRAIL-resistant primary B-cell chronic lymphocytic leukemia (B-CLL) cells with histone deacetylase inhibitors (HDACis) could render them susceptible to killing by TRAIL. We found that HDAC inhibition in B-CLL cells led to increased TRAIL receptor expression, increased caspase activation, decreased expression of antiapoptotic regulators such as Bcl-2, and ultimately, enhanced TRAIL-ind......
POSTED 06/14/2009 at 06:29 PM --
|
EHA 2009: Ofatumumab Shows High Response Rate in Chronic Lymphocytic Leukemia Patients
Updated results show that the drug is effective in CLL patients who are refractory to other agents, an indication that has just been recommended for FDA approval. Medscape Medical News (Source: Medscape Medical News Headlines)...
POSTED 06/11/2009 at 11:11 AM --
|
Strategy Aims at Making Ofatumumab First-Line Treatment for CLL
BERLIN (EGMN) - Ofatumumab, a new monoclonal antibody that targets B cells, may eventually emerge as a first-line drug for previously untreated patients with chronic lymphocytic leukemia, said the primary... (Source: OncologySTAT Latest News)...
POSTED 06/10/2009 at 09:09 PM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Total Balance
Men's Plus |
|
"The restoration and maintenance of normal organ and brain function, a strong immune system, and the balancing of hormones is the key to vibrant health and in avoiding premature-aging!" |
|
CLICK HERE
for more info... |
|
|
